Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Sage Therapeutics Inc's Business Segments
Sage Therapeutics Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
1
Largest Segment
Corporate and Reconciling Items
Total Revenue
$ 32
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Corporate and Reconciling Items100%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Corporate and Reconciling Items | $ 32 | 100% |
Revenue by Product & Service Category - FY
- Collaboration Revenue Related Party73.3%
- Other Revenue26.7%
- Other Collaboration Revenue Related Party1.2%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Collaboration Revenue Related Party | $ 23 | 73.3% |
| Other Revenue | $ 8 | 26.7% |
| Other Collaboration Revenue Related Party | $ 0 | 1.2% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Annual Results
Revenue Share by Reportable Segment - FY
- Corporate and Reconciling Items100%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Corporate and Reconciling Items | $ 32 | 100% |
Description of Sage Therapeutics Inc
Sage Therapeutics Inc is a renowned biopharmaceutical company that focuses on discovering, developing, and commercializing novel medicines for the treatment of central nervous system (CNS) disorders. The company was founded in 2010 and is headquartered in Cambridge, Massachusetts, United States.
Sage Therapeutics is committed to addressing critical unmet needs in healthcare by targeting disorders such as major depressive disorder (MDD), postpartum depression (PPD), Parkinson's disease, essential tremor, and status epilepticus. They leverage their expertise in neuroscience and drug development to create innovative therapies that can potentially provide significant benefits to patients suffering from these challenging conditions.
The company's flagship product is Zulresso (brexanolone), which is the first and only medication approved by the U.S. Food and Drug Administration (FDA) specifically for the treatment of postpartum depression. Zulresso is administered via continuous intravenous infusion over a 60-hour period, during which it acts on specific brain receptors to balance the levels of certain neurotransmitters implicated in mood regulation.
In addition to Zulresso, Sage Therapeutics has an extensive pipeline of promising drug candidates at various stages of clinical development. Their lead oral compound, SAGE-217, is being developed as a potential treatment for MDD, PPD, bipolar disorder, and major depressive disorder with mixed features. SAGE-217 targets the GABA receptors in the brain, aiming to provide rapid and sustained relief of symptoms with improved tolerability compared to traditional antidepressants.
Sage Therapeutics also focuses on developing therapies for movement disorders, such as Parkinson's disease and essential tremor. They have multiple active programs targeting these indications, including SAGE-324, which is an orally administered modulator of the GABA receptor intended to reduce excessive neuronal activity and address motor symptoms.
The company's approach to drug development involves utilizing a combination of cutting-edge scientific techniques, clinical research, and strategic collaborations with academic institutions and other industry partners. They emphasize precision medicine and personalized treatment options, aiming to identify patient subpopulations that may respond more favorably to their therapies and tailoring treatments accordingly.
Sage Therapeutics has assembled a team of experienced scientists, clinicians, and industry professionals dedicated to making a meaningful impact on patients' lives. Their research and development efforts are supported by a strong financial position, with partnerships with major pharmaceutical companies and significant investment from venture capital firms.
Overall, Sage Therapeutics Inc is a pioneer in the field of CNS disorders, leveraging innovative science and drug development strategies to bring transformative therapies to patients suffering from a range of debilitating conditions. They are committed to improving the standard of care in neuroscience and making a lasting impact on patients' quality of life.
Sage Therapeutics is committed to addressing critical unmet needs in healthcare by targeting disorders such as major depressive disorder (MDD), postpartum depression (PPD), Parkinson's disease, essential tremor, and status epilepticus. They leverage their expertise in neuroscience and drug development to create innovative therapies that can potentially provide significant benefits to patients suffering from these challenging conditions.
The company's flagship product is Zulresso (brexanolone), which is the first and only medication approved by the U.S. Food and Drug Administration (FDA) specifically for the treatment of postpartum depression. Zulresso is administered via continuous intravenous infusion over a 60-hour period, during which it acts on specific brain receptors to balance the levels of certain neurotransmitters implicated in mood regulation.
In addition to Zulresso, Sage Therapeutics has an extensive pipeline of promising drug candidates at various stages of clinical development. Their lead oral compound, SAGE-217, is being developed as a potential treatment for MDD, PPD, bipolar disorder, and major depressive disorder with mixed features. SAGE-217 targets the GABA receptors in the brain, aiming to provide rapid and sustained relief of symptoms with improved tolerability compared to traditional antidepressants.
Sage Therapeutics also focuses on developing therapies for movement disorders, such as Parkinson's disease and essential tremor. They have multiple active programs targeting these indications, including SAGE-324, which is an orally administered modulator of the GABA receptor intended to reduce excessive neuronal activity and address motor symptoms.
The company's approach to drug development involves utilizing a combination of cutting-edge scientific techniques, clinical research, and strategic collaborations with academic institutions and other industry partners. They emphasize precision medicine and personalized treatment options, aiming to identify patient subpopulations that may respond more favorably to their therapies and tailoring treatments accordingly.
Sage Therapeutics has assembled a team of experienced scientists, clinicians, and industry professionals dedicated to making a meaningful impact on patients' lives. Their research and development efforts are supported by a strong financial position, with partnerships with major pharmaceutical companies and significant investment from venture capital firms.
Overall, Sage Therapeutics Inc is a pioneer in the field of CNS disorders, leveraging innovative science and drug development strategies to bring transformative therapies to patients suffering from a range of debilitating conditions. They are committed to improving the standard of care in neuroscience and making a lasting impact on patients' quality of life.
Sage Therapeutics Inc. is a biopharmaceutical company focused on developing and commercializing innovative treatments for central nervous system (CNS) disorders. The company’s research and development efforts are centered around understanding and modifying the brain’s neurochemistry to address unmet medical needs in mental health and neurological conditions. Below is an extensive description of the segments, products, and services that Sage Therapeutics offers:
Segments
1. Depression and Mood Disorders:
- Sage Therapeutics concentrates heavily on developing treatments for major depressive disorder (MDD) and other mood disorders. The company’s approach often involves targeting receptor systems to provide rapid symptom relief.
2. Neurological Disorders:
- Beyond mood disorders, Sage Therapeutics explores therapies for a range of neurological conditions, including epilepsy and neurodegenerative diseases. The aim is to develop medications that enhance synaptic function and improve cognitive performance.
3. Neonatal Care:
- Sage also focuses on innovations in neonatal care, specifically addressing conditions that affect newborns, such as neonatal hypoxic-ischemic encephalopathy by developing therapies that can mitigate long-term neurological damage.
Products
1. Zuranolone (SAGE-217):
- Zuranolone is a novel, oral medication designed for the treatment of MDD and postpartum depression (PPD). It acts on the GABA receptor system, providing a rapid onset of action with the potential for a significant reduction in depression symptoms. Zuranolone has been subjected to ongoing clinical trials to establish its safety, efficacy, and dosing profiles.
2. SAGE-324:
- This is an investigational compound aimed at treating epilepsy. SAGE-324 is designed to modulate the activity of GABA receptors selectively and is being evaluated for its potential to reduce seizure frequency.
3. SAGE-718:
- An investigational product aimed at treating Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative disorders. SAGE-718 focuses on enhancing cognitive function and is under development to explore its impact on diseases that involve cognitive impairment.
Services
1. Clinical Research and Development:
- Sage Therapeutics invests heavily in clinical research to explore new indications for their products, improve understanding of CNS disorders, and gather data for regulatory approvals. Collaboration with various research institutions and health care organizations to advance studies in depression and other CNS diseases is a key component of their service offerings.
2. Patient Support Programs:
- Sage Therapeutics provides services to support patients receiving treatment with their products. This can include therapy education, access to resources for managing conditions, and guidance on medication adherence. Their goal is to ensure that patients have the support necessary to optimize treatment outcomes.
3. Collaborative Partnerships:
- The company often engages in partnerships with academic institutions, pharmaceutical companies, and research organizations. These collaborations help leverage expertise and resources to further develop their pipeline products, which can result in shared knowledge and clinical advancement.
4. Regulatory Support:
- Sage Therapeutics also works extensively with regulatory authorities to facilitate drug approvals and ensure compliance with health regulations. This includes preparing submissions for Investigational New Drug (IND) applications, New Drug Applications (NDAs), and maintaining communication with the FDA.
Summary
Sage Therapeutics Inc. is positioned as a pioneering force in the field of CNS disorders, with a rich pipeline of products primarily focused on depression and neurological disorders. The company is committed to developing innovative therapies that can potentially change the landscape of treatment for mental health and neurological health conditions. Their extensive portfolio of drugs in various stages of development, along with comprehensive patient support and collaborative research efforts, underscores their dedication to advancing psychiatric and neurological care.
Segments
1. Depression and Mood Disorders:
- Sage Therapeutics concentrates heavily on developing treatments for major depressive disorder (MDD) and other mood disorders. The company’s approach often involves targeting receptor systems to provide rapid symptom relief.
2. Neurological Disorders:
- Beyond mood disorders, Sage Therapeutics explores therapies for a range of neurological conditions, including epilepsy and neurodegenerative diseases. The aim is to develop medications that enhance synaptic function and improve cognitive performance.
3. Neonatal Care:
- Sage also focuses on innovations in neonatal care, specifically addressing conditions that affect newborns, such as neonatal hypoxic-ischemic encephalopathy by developing therapies that can mitigate long-term neurological damage.
Products
1. Zuranolone (SAGE-217):
- Zuranolone is a novel, oral medication designed for the treatment of MDD and postpartum depression (PPD). It acts on the GABA receptor system, providing a rapid onset of action with the potential for a significant reduction in depression symptoms. Zuranolone has been subjected to ongoing clinical trials to establish its safety, efficacy, and dosing profiles.
2. SAGE-324:
- This is an investigational compound aimed at treating epilepsy. SAGE-324 is designed to modulate the activity of GABA receptors selectively and is being evaluated for its potential to reduce seizure frequency.
3. SAGE-718:
- An investigational product aimed at treating Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative disorders. SAGE-718 focuses on enhancing cognitive function and is under development to explore its impact on diseases that involve cognitive impairment.
Services
1. Clinical Research and Development:
- Sage Therapeutics invests heavily in clinical research to explore new indications for their products, improve understanding of CNS disorders, and gather data for regulatory approvals. Collaboration with various research institutions and health care organizations to advance studies in depression and other CNS diseases is a key component of their service offerings.
2. Patient Support Programs:
- Sage Therapeutics provides services to support patients receiving treatment with their products. This can include therapy education, access to resources for managing conditions, and guidance on medication adherence. Their goal is to ensure that patients have the support necessary to optimize treatment outcomes.
3. Collaborative Partnerships:
- The company often engages in partnerships with academic institutions, pharmaceutical companies, and research organizations. These collaborations help leverage expertise and resources to further develop their pipeline products, which can result in shared knowledge and clinical advancement.
4. Regulatory Support:
- Sage Therapeutics also works extensively with regulatory authorities to facilitate drug approvals and ensure compliance with health regulations. This includes preparing submissions for Investigational New Drug (IND) applications, New Drug Applications (NDAs), and maintaining communication with the FDA.
Summary
Sage Therapeutics Inc. is positioned as a pioneering force in the field of CNS disorders, with a rich pipeline of products primarily focused on depression and neurological disorders. The company is committed to developing innovative therapies that can potentially change the landscape of treatment for mental health and neurological health conditions. Their extensive portfolio of drugs in various stages of development, along with comprehensive patient support and collaborative research efforts, underscores their dedication to advancing psychiatric and neurological care.